(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of -13.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Kymera Therapeutics's revenue in 2026 is $51,475,000.On average, 24 Wall Street analysts forecast KYMR's revenue for 2026 to be $7,256,024,095, with the lowest KYMR revenue forecast at $3,361,538,591, and the highest KYMR revenue forecast at $11,141,790,295. On average, 24 Wall Street analysts forecast KYMR's revenue for 2027 to be $3,511,987,720, with the lowest KYMR revenue forecast at -$1,047,961,671, and the highest KYMR revenue forecast at $8,416,596,404.
In 2028, KYMR is forecast to generate $3,484,431,428 in revenue, with the lowest revenue forecast at -$2,015,310,906 and the highest revenue forecast at $7,044,951,124.